<div id="readability-page-1"><p>In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Quantum-Si, with a price target of <span id="expert-recommendation-target">$4.00</span>.</p><h3>TipRanks Black Friday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for the data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Personalis, and Evaxion Biotech. According to TipRanks, Ramakanth has an average return of <span>17.9%</span> and a 43.00% success rate on recommended stocks. </p> <p>In addition to H.C. Wainwright, Quantum-Si also received a Buy from Alliance Global Partners’s Scott Henry in a report issued on November 7. However, on November 14, TR | OpenAI – 4o reiterated a Hold rating on Quantum-Si (NASDAQ: QSI).</p></div>

<p>H.C. Wainwright's Swayampakula Ramakanth maintains a Buy rating for Quantum-Si with a $4.00 price target. Ramakanth, who covers the Healthcare sector, has a 17.9% average return and a 43% success rate. Quantum-Si also received a Buy rating from Alliance Global Partners, while TR | OpenAI reiterated a Hold rating. The report highlights investment insights and analyst performance.</p>

H.C. Wainwright Sticks to Its Buy Rating for Quantum-Si (QSI)